立体定向消融体部放射治疗肺转移瘤：证据何在，我们又如何运用这些证据？
Stereotactic Ablative Body Radiotherapy for Lung Metastases: Where is the Evidence and What are We Doing With It?
作者信息
Siva Shankar, Slotman Ben J
机构信息
Department of Radiation Oncology, Peter MacCallum Cancer Centre, East Melbourne, Australia.
Department of Radiation Oncology, VU University Medical Center, Amsterdam, The Netherlands.
出版信息
Semin Radiat Oncol. 2017 Jul;27(3):229-239. doi: 10.1016/j.semradonc.2017.03.003. Epub 2017 Mar 21.
This review provides an overview of the use of stereotactic ablative body radiotherapy (SABR) for pulmonary metastases. The local control rates after SABR are generally >90%. Whether this also translates into a significant improvement in overall survival is the subject of ongoing studies. New exciting opportunities including the integration of SABR with targeted and immune therapies as well as some competing treatment strategies are discussed.
本综述概述了立体定向消融体部放疗（SABR）在肺转移瘤治疗中的应用。SABR后的局部控制率一般>90%。这是否也能转化为总生存期的显著改善仍是正在进行的研究课题。文中还讨论了一些令人兴奋的新机遇，包括SABR与靶向治疗和免疫治疗的联合应用，以及一些竞争性的治疗策略。
Zotero 插件